Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Podobne zapisy

• Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
  od: Elstein, D, i wsp.
  Wydane: (2004)
• Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
  od: Platt, F, i wsp.
  Wydane: (2001)
• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
  od: Andersson, U, i wsp.
  Wydane: (2000)
• Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
  od: Walden, C, i wsp.
  Wydane: (2006)
• NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
  od: Jeyakumar, M, i wsp.
  Wydane: (2004)